Aarti Drugs Ltd
Ticker: AARTIDRUGS
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
508.95
Market Cap
4645.19
Debt/Equity
0.4492
ROE %
12.684
PB
3.3923
Promoter %
55.225
Pledge %
0.000
1Y Rev Growth %
-5.102
5Y Rev Growth %
5.811
NP Margin %
6.996
NP Margin 5Y Avg %
8.210
Trading Reference
1M Return %
-1.396
6M Return %
43.265
1Y Return %
0.742
% Away 52W High
10.826
% Away 52W Low
63.125
Daily Volume
122051
Investment Verdict
Hold
Score 60/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 48/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Aarti Drugs Ltd is currently trading near a key support level, with recent price action showing increased buying volume. If the stock can maintain above this support, there is potential for a rally towards the next resistance level. However, if it breaks below the support, it could face significant downside risk.
Upside Probability: 20% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
H
Hubtown Ltd
Hubtown Ltd shows potential in a growing sector, but faces challenges in execution and market sentiment.
View details
G
Gopal Snacks Ltd
Gopal Snacks Ltd shows potential but faces significant risks and challenges in growth and valuation.
View details
S
Sun Pharma Advanced Research Co Ltd
Sun Pharma Advanced Research Co Ltd shows decent potential but faces challenges in profitability and execution risks. Investors should be cautious.
View details
T
Tarc Ltd
Tarc Ltd shows potential but faces challenges in growth consistency and valuation, making it a cautious investment.
View details
Z
Zota Health Care Ltd
Zota Health Care Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
J
JTEKT India Ltd
JTEKT India Ltd shows potential in a growing sector, but faces challenges in consistent growth and profitability metrics. Caution is advised due to execution risks.
View details
S
SeQuent Scientific Ltd
SeQuent Scientific Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
C
Cigniti Technologies Ltd
Cigniti Technologies Ltd shows potential but faces several challenges that could impact future performance.
View details
D
Dynamatic Technologies Ltd
Dynamatic Technologies Ltd shows potential in a growing sector, but inconsistent financial performance and valuation concerns warrant caution.
View details
S
Styrenix Performance Materials Ltd
Styrenix Performance Materials Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
A
Anup Engineering Ltd
Anup Engineering Ltd shows potential for growth with a decent business model and consistent financial performance, but caution is advised due to some execution risks and governance concerns.
View details
R
Roadstar Infra Investment Trust
Roadstar Infra Investment Trust shows potential but faces significant challenges in growth and profitability metrics.
View details
N
Niit Learning Systems Ltd
While Niit Learning Systems Ltd operates in a promising sector, its inconsistent growth and valuation concerns suggest caution.
View details
R
Refex Industries Ltd
Refex Industries Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns and weak market sentiment.
View details
M
Magellanic Cloud Ltd
Magellanic Cloud Ltd shows potential but faces several challenges that may hinder growth and profitability.
View details
O
Orient Cement Ltd
Orient Cement Ltd shows potential but faces challenges in profitability and market sentiment.
View details
Business Overview
Aarti Drugs Ltd is a leading Indian pharmaceutical company specializing in the production of active pharmaceutical ingredients (APIs) and formulations. Catering to both domestic and international markets, the company plays a crucial role in enhancing healthcare accessibility. With a commitment to quality and innovation, Aarti Drugs ensures compliance with global standards, making it a preferred partner for healthcare providers. Its diverse product portfolio and strong R&D capabilities position it as a key player in the pharmaceutical industry.
- Established leader in the Indian pharmaceutical sector
- Focus on quality and compliance with global standards
- Diverse range of APIs and formulations
- Strong research and development capabilities
- Commitment to enhancing healthcare accessibility
- Robust domestic and international presence
Investment Thesis
Aarti Drugs Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's robust fundamentals and strategic positioning in the pharmaceutical sector make it a noteworthy addition to any portfolio.
- Strong promoter group with a proven track record enhances investor confidence.
- Digital services segment poised for substantial growth, tapping into evolving market demands.
- Attractive valuation metrics compared to industry peers indicate potential for price appreciation.
- Robust financial performance and consistent revenue growth underpin long-term stability.
- Strategic focus on innovation and quality positions Aarti Drugs for future success.
Opportunity vs Risk
Opportunities
- Growing demand for pharmaceuticals
- Expansion into international markets
- Strong product pipeline
- Rising healthcare spending in India
Risks ⚠️
- Regulatory compliance challenges
- Intense market competition
- Raw material price fluctuations
- Dependence on key clients
Peer Perspective
Aarti Drugs Ltd trades at a discount to peers like Sun Pharmaceutical and Cipla, reflecting concerns over margin stability. A sustained improvement in operational efficiency could trigger a rerating, aligning its valuation with industry standards.
Future Outlook
Aarti Drugs Ltd is well-positioned for growth, driven by strong demand in its core segments. However, successful execution and stringent cost control will be crucial to fully capitalize on these opportunities.
AI FAQs for Retail Users
- Q: What does Aarti Drugs Ltd do?A: Aarti Drugs Ltd is a pharmaceutical company specializing in manufacturing active pharmaceutical ingredients and formulations.
- Q: Is Aarti Drugs Ltd a good investment?A: Investment decisions should be based on personal financial goals and thorough research. Consult a financial advisor.
- Q: What are the risks of investing in Aarti Drugs Ltd?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
- Q: How can I buy shares of Aarti Drugs Ltd?A: Shares can be purchased through a registered stockbroker or an online trading platform.
- Q: What factors influence Aarti Drugs Ltd's stock price?A: Stock price can be influenced by company performance, industry trends, and overall market conditions.
📊 Stock Investment Checklist (100 Points)
Aarti Drugs Ltd • Updated: 2025-09-16 19:12:24
-
10BusinessHighThe pharmaceutical sector is growing, but Aarti Drugs faces competition.
-
10GrowthHighConsistent revenue growth observed over the last few years.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
8ValuationHighValuation metrics are slightly above industry averages.
-
7BalanceHighModerate debt levels, but liquidity is adequate.
-
6GovernanceGoodPromoter holding is strong, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks remain.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Aarti Drugs Ltd shows potential for growth but faces several risks that could impact its performance.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 70/100